Clinical trials for Lymphoma

95 currently recruiting clinical trials

Phase 2 Lymphoma #NCT05283720 #2023-505347-38-00
B cell lymphoma Mantel cell lymphoma None 1 2 3 or more
Bispecific T-cell engager antibodies
8 recruiting sites
Abbvie
Phase 2 Lymphoma #NCT06534437 #2024-513098-31-00
B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Bispecific T-cell engager antibodies Monoclonal antibodies
Systemic Treatment-Naive
7 recruiting sites
Ryvu Therapeutics SA
Phase 2 Lymphoma #NCT05139017 #2022-502646-27-00
B cell lymphoma Large B cell lymphoma None Treated / Controled 1 2 3 or more Car-T Autologous stem cell transplant
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 2 Lymphoma #NCT06526793
B cell lymphoma Large B cell lymphoma Follicular lymphoma None Treated / Controled > 60 ml/min 50-60 ml/min 30-50 ml/min 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca
Phase 2 Lymphoma #NCT04728893 #2023-504931-42-00
B cell lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma None Treated / Controled 1 2 3 or more Chemotherapy Targeted therapy Monoclonal antibodies
Systemic Treatment-Naive
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Lymphoma #NCT06482684 #2022-502405-15-01
B cell lymphoma Mantel cell lymphoma Early (stage I and II) Disseminated (stage III and IV) None > 60 ml/min None Systemic Treatment-Naive
2 recruiting sites
Ludwig-Maximilians - Université de Munich
Phase 2 Lymphoma #NCT03328078 #2024-513312-95-00
B cell lymphoma Primary cerebral lymphoma 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Curis, Inc.
Phase 2 Lymphoma #NCT06271057 #2023-506705-20-00
B cell lymphoma Large B cell lymphoma Primary mediastinal lymphoma Indolent transformed lymphoma > 60 ml/min 2 3 or more
Systemic Treatment-Naive
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2 Lymphoma #NCT06588478 #2024-515689-15-01
B cell lymphoma Lymphocytic lymphoma None None Systemic Treatment-Naive
6 recruiting sites
Loxo Oncology
Phase 2 Lymphoma #NCT06588478 #2024-515689-15-01
B cell lymphoma Lymphocytic lymphoma None 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
6 recruiting sites
Loxo Oncology